Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care
JAMA Network Open · 25.03.2026 · 9 (3) · e263050
DOI: 10.1001/jamanetworkopen.2026.3050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 25.03.2026. Verfasst von Berkeley Franz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Medicine, Ohio University Heritage College of Osteopathic Medicine, Athens. Hauptthemen laut MEDLINE: Buprenorphine, Primary Health Care, Rural Health Services, Opioid-Related Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Abstract (Originalsprache)
Importance Although buprenorphine is highly effective at preventing overdose, access is limited in rural areas. Rural primary care is a critical site to expand access; prescribing support tailored for this setting is urgently needed.
Objective
To test the feasibility and preliminary effectiveness of a brief buprenorphine prescribing support program (BPSP) tailored for rural primary care professionals (PCPs). Design, Setting, and Participants This cluster randomized pilot clinical trial compared 27 Ohio community health centers with 63 PCPs (10 physicians, 50 nurse practitioners, and 3 physician assistants) receiving the support program at baseline and immediately after the intervention with those receiving only copies of the American Society of Addiction Medicine’s buprenorphine prescribing guidelines. Data were collected from July 25, 2024, to February 28, 2025.
Interventions
The BPSP is a brief, hour-long, asynchronous and online training program, followed by an optional, live booster session, that provides clinical skills on buprenorphine prescribing, addresses misinformation on the safety of buprenorphine, and addresses stigma toward buprenorphine. Health centers were randomized with 2 centers allocated to the intervention for every 1 allocated to the control condition. Main Outcomes and Measures Primary implementation outcomes were feasibility (measured via the 4-item Feasibility of Intervention Measure [scale of 1 to 5, with higher scores indicating greater feasibility]), acceptability (measured via the 4-item Acceptability of Intervention Measure [scale of 1 to 5, with lhigher scores indicating greater acceptability]), and appropriateness (measured via the 4-item Intervention Appropriateness Measure [scale of 1 to 5, with higher scores indicating greater appropriateness]) of the BPSP; willingness to treat opioid use disorder (OUD) in primary care (using a measure developed and tested with a different sample of PCPs); and likelihood of prescribing buprenorphine in the next 6 months (measured via a 5-point Likert scale ranging from 1.00 [extremely unlikely] to 5.00 [extremely likely]).
Results
Of the 63 participating PCPs, 48 participants were allocated to the intervention condition and 15 to the control condition (49 female [78%]; mean [SD] age, 45.5 [11.4] years). Forty-nine participants (78%) practiced in rural areas and 10 (16%) had ever prescribed buprenorphine. Participants receiving the BPSP rated it as highly feasible (median score, 4.25 [IQR, 4.00-5.00]), acceptable (median score, 4.88 of 5.00 [IQR, 4.00-5.00]), and appropriate (median score, 5.00 of 5.00 [IQR, 4.00-5.00]). Participants receiving the BPSP had significantly higher willingness to treat OUD; 86% of rank comparisons improved post intervention. Intention to prescribe buprenorphine in the next 6 months also significantly increased; 98% of rank comparisons improved post intervention. Participants who completed the BPSP showed significant improvements in having correct information about buprenorphine, had greater confidence treating addiction and prescribing buprenorphine, and had lower stigma and greater empathy toward patients with OUD. Conclusions and Relevance In this cluster randomized clinical trial of the BPSF, brief prescribing support was feasible, acceptable, and appropriate for implementation in rural primary care, and intentions to prescribe buprenorphine increased. A larger trial is needed to confirm preliminary findings. Trial Registration ClinicalTrials.gov Identifier: NCT05505227
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Social Medicine, Ohio University Heritage College of Osteopathic Medicine, Athens.
- The Institute to Advance Population Health, Athens, Ohio.
- School of Management and Labor Relations, Rutgers University, Piscataway, New Jersey.
- Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora.
- Department of Psychiatry and Behavioral Health, Ohio State University Wexner Medical Center, Columbus.
- Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill.
Förderung
- NIDA NIH HHS
Zitieren
APA
Franz, B., Dhanani, L. Y., Brook, D., Hall, O. T., Go, V., Simon, J. E., Fenstemaker, C., & Miller, W. C. (2026). Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care. JAMA Network Open, 9(3), e263050. https://doi.org/10.1001/jamanetworkopen.2026.3050
Vancouver
Franz B, Dhanani LY, Brook D, Hall OT, Go V, Simon JE, et al. Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care. JAMA Network Open. 2026;9(3):e263050. doi:10.1001/jamanetworkopen.2026.3050
BibTeX
@article{Franz2026,
author = {Franz, Berkeley and Dhanani, Lindsay Y and Brook, Daniel and Hall, O Trent and Go, Vivian and Simon, Janet E and Fenstemaker, Cheyenne and Miller, William C},
title = {Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {3},
pages = {e263050},
doi = {10.1001/jamanetworkopen.2026.3050}
}
EUVIMED